Combination therapy for dyslipidemia: safety and regulatory considerations

This publication has 39 references indexed in Scilit:

• ACC/AHA/NHLBI clinical advisory on the use and safety of statins
  Journal of the American College of Cardiology, 2002
• Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
  Published by Elsevier ,2002
• The impact of the national cholesterol education program adult treatment panel III guidelines on drug development
  The American Journal of Cardiology, 2002
• Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  JAMA, 2001
• New statins and new doses of older statins
  Current Atherosclerosis Reports, 2001
• Does differing metabolism by cytochrome P450 have clinical importance?
  Current Atherosclerosis Reports, 2000
• Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients
  New England Journal of Medicine, 2000
• Treating patients with documented atherosclerosis to national cholesterol education program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
  Journal of the American College of Cardiology, 1998
• The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
  Archives of internal medicine (1960), 1997
• Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans*
  Clinical Pharmacology & Therapeutics, 1995